Showing papers in "Biology of Blood and Marrow Transplantation in 2016"

TL;DR: This paper developed guidelines through international expert consensus opinion to standardize the diagnosis and clinical staging of acute graft-versus-host disease (GVHD) for use in a large international GVHD research consortium.

TL;DR: Risk factors associated with development of VOD/SOS, including pretransplantation patient characteristics and factors related to stem cell transplantation, that can facilitate patient stratification according to risk are summarized.

TL;DR: An organ system-based overview that emphasizes the most relevant COG recommendations (with accompanying evidence grade) for the long-term follow-up care of childhood HCT survivors (regardless of current age) based on a rigorous review of the available evidence is provided.

TL;DR: AZA is well tolerated after transplantation and appears to have the capacity to reduce the relapse risk in patients who demonstrate a CD8+ T cell response to tumor antigens, although these observations require confirmation in a prospective clinical trial.

TL;DR: Data suggest that FAM was well tolerated and that treatment with FAM and steroid pulse may halt pulmonary decline in new-onset BOS in the majority of patients and permit reductions in systemic steroid exposure, which collectively may improve quality of life.

TL;DR: HIDT produced similar long-term survival with lower rates of chronic GVHD than optimally matched MUDT and should be considered a standard of care option for patients lacking a matched sibling donor.

TL;DR: Complement blocking therapy is associated with improved survival in HSCT patients with high-risk TMA who historically have dismal outcomes, but eculizumab pharmacokinetics in HS CT recipients differ significantly from reports in other diseases like atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.

TL;DR: Seven patients with CRS were treated with tocilizumab, resulting in a complete resolution of their CRS symptoms, and anti-IL-6 receptor therapy is associated with rapid resolution of the CRS Symptoms.

TL;DR: A phase 3, multicenter, randomized trial of transplantation of bone marrow (BM) versus peripheral blood stem cells (PBSC) from unrelated donors showed no significant differences in 2-year survival between these graft sources.

TL;DR: It is suggested that JAK1/2 inhibitors should be continued near to the start of conditioning therapy, and the favorable outcomes of patients who experienced clinical improvement with JAK 1/2 inhibitor therapy before HCT were particularly encouraging, and need further prospective validation.

TL;DR: A phase I study infusing escalating doses of NK cells from an HLA haploidentical-related donor-selected for alloreactivity when possible-as a component of the preparative regimen for allotransplantation from a separate HLA-identical donor demonstrates a lack of major toxicity attributable to third-party NK cell infusions delivered in combination with an H LA-compatible allogeneic transplantation.

TL;DR: The results underscore the successful use of a chemotherapy-free regimen in MRD HSCT for high-risk adult SCD patients and demonstrates a high cure rate, absence of GVHD or mortality, and improvement in QoL including the applicability of this regimen in ABO mismatched cases.

TL;DR: The data support the safety of haploidentical NK cell infusion after allogeneic HCT, with a slight trend toward greater expression of KIR2DL2/2DL3/2DS2 at 14 days in patients who survived longer than 6 months fromNK cell infusion compared with those who died within 6 months of NK cell therapy.

TL;DR: This "Considerations" document is a list of most frequently asked questions regarding personalized busulfan dosing and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians.

TL;DR: This multicenter prospective study confirms the high rate of late aGVHD and cGVHD syndromes and supports the need for continuous close monitoring and development of more effective GVHD treatment strategies to improve HCT success.

TL;DR: This is the first analysis on OM in allogeneic HSCT patients with respect to conditioning regimens, and it is observed that RIC regimens led to a high incidence of OM similar to that of MA regimens.

TL;DR: Cord blood may be the first choice alternative to 8/8 UBMT for both AML and ALL, and UCBT showed similar overall survival (OS), whereas 7/8UBMT showed inferior OS.

TL;DR: Results provide broad support for the therapeutic value of HLA-identical sibling HCT for children with SCD and serve as the basis for a strong recommendation in favor of the option of HCT when a suitable donor is available.

TL;DR: Clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies are established.

TL;DR: The current status, including recent trends, of haplo-HSCT is learned from speakers from major transplant centers in 3 regions (Asia, Europe, and North America) to present at its annual WBMT Joint Session.

TL;DR: PTCy in combination with tacrolimus and MMF is a safe and effective GVHD prophylaxis for unrelated PBSC transplantation with a better safety profile compared with ATG with reduced incidence of veno-occlusive disease, cytomegalovirus reactivation, invasive mycosis, and reduced severity of mucositis.

TL;DR: In this review, insights on the biology of GI GVHD, interaction of microflora and metabolome with the hosts, identification of potential new target organs, and identification and targeting of novel T cell-signaling pathways are discussed.

TL;DR: It is concluded that T cell-replete haplo-ID HSCT followed by post-transplantation high-dose- cyclophosphamide in patients over 55 years is associated with promising results, similar to MRD HSCT, and is deserving prospective evaluation.

TL;DR: It is suggested that reduced-intensity SCT is a viable treatment option for elderly AML patients with a 3-year RFS of 35% for those over the age of 60, and a meta-analysis of previous articles argues against using age per se as the sole criterion against SCT and demonstrates consistency among reports.

TL;DR: It is determined that gut colonization by antibiotic-resistant bacteria decreases the overall survival of patients undergoing alloSCT by increasing nonrelapse mortality and the incidences of systemic infection and acute GVHD.

TL;DR: Safety and efficacy resultswere consistent with prior studies of defibrotide in hepatic VOD/SOS, and subgroup analyses lend support to the use of the 25 mg/kg/day dose.

TL;DR: Examining the role of alloHCT in first remission in relationship to the allelic ratio and presence or absence of nucleophosmin 1 mutations in the Study Alliance Leukemia AML2003 trial provides additional evidence that allo HCT inFirst remission improves EFS and OS in patients with HR(FLT3-ITD) AML and in patientswith LR(FLt3- ITD)AML and wild-type NPM1.

TL;DR: Children who underwent SCT and did not survive were likely to die in a medicalized setting, irrespective of PPC, and among children who died in the hospital, those who received PPC were morelikely to die outside the intensive care unit.

TL;DR: This investigation shows that a Cox regression model applied to the entire cohort is often a more powerful tool in detecting treatment effect as compared with a matched study.

TL;DR: The immunodeficiency scoring index (ISI) that was originally developed for respiratory syncytial virus may help identify HCT recipients at risk for progression to LRI and mortality after influenza infection and should be monitored more closely.